In a bid to expand its respiratory product portfolio,
) announced that it has entered into a definitive merger agreement
to acquire California-based biotechnology company InterMune, Inc. (
) for $74.00 per share or $8.3 billion.
The offer price of $74.00 per share represents a premium of
37.5% to InterMune's closing price of $53.80 on Aug 22, 2014.
The agreement has been approved by boards of both companies.
Roche will commence a tender offer by Aug 29 to acquire all
outstanding shares of InterMune.
Roche expects the transaction to be neutral to the bottom line
on a core basis by 2015 and accretive from 2016 onward.
We note that InterMune focuses on the research, development and
commercialization of innovative therapies in pulmonology and
fibrotic diseases. InterMune's lead drug Esbriet is approved for
idiopathic pulmonary fibrosis (IPF) in the EU (2011) and Canada
(2012). The drug is under review in the U.S.
The acquisition will further expand Roche's respiratory product
portfolio, which markets Pulmozyme and Xolair in the U.S.
We remind investors that the FDA recommended InterMune to
conduct an additional phase III trial to support the efficacy of
Esbriet after rejecting its New Drug Application (NDA) in 2010. In
May 2014, InterMune resubmitted its NDA for Esbriet based on
encouraging top-line results from the phase III study, ASCEND,
which was announced in Feb 2014.
In Jul 2014, Esbriet was granted breakthrough therapy
designation in the U.S. A final decision from the FDA on the
approval of Esbriet is expected by Nov 23, 2014.
Roche is well placed in the oncology market. In particular,
Roche is a leader in the breast cancer market with its HER2
franchise. The HER2 franchise includes oncology drugs like
Herceptin, Perjeta and Kadcyla. We are impressed by the company's
efforts to expand its portfolio beyond oncology in the field of
immunology, ophthalmology and respiratory.
Roche has been quite active on the acquisition front of late.
Earlier in the month, Roche announced that it has entered into an
agreement to acquire Denmark-based privately-held biopharmaceutical
company Santaris Pharma to expand the discovery and development of
In Jul 2014, Roche entered into a definitive agreement to
acquire privately-held biotechnology company Seragon
Pharmaceuticals, Inc. The acquisition will provide Roche rights to
Seragon's entire portfolio of investigational next-generation oral
selective estrogen receptor degraders (SERDs) for the potential
treatment of hormone receptor-positive breast cancer.
Roche currently carries a Zacks Rank #3 (Hold). Some
better-ranked stocks in the broader healthcare sector include
) and AstraZeneca (
). While Allergan sports a Zacks Rank #1 (Strong Buy), AstraZeneca
is a Zacks Rank #2 (Buy) stock.
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
ROCHE HLDG LTD (RHHBY): Free Stock Analysis
ASTRAZENECA PLC (AZN): Free Stock Analysis
INTERMUNE INC (ITMN): Free Stock Analysis
ALLERGAN INC (AGN): Free Stock Analysis Report
To read this article on Zacks.com click here.